PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) has submitted an application to health regulators in Abu Dhabi to begin a genomics-based Phase 2a study of its investigational drug Teverelix in women with endometriosis, a move that could position the company at the intersection of women’s health and precision medicine research.
The application was filed with the Department of Health – Abu Dhabi for the PRECISION-E2 trial, which is designed to evaluate how genetic variation may influence treatment response in patients with symptomatic endometriosis.
The study is expected to enroll approximately 84 women across multiple sites in the United Arab Emirates and will test three Teverelix treatment regimens administered through subcutaneous and intramuscular injection.
A central feature of the trial is its planned integration with the Emirati Genome Program, one of the world’s largest national genomics initiatives. Researchers intend to examine whether genetic differences in estrogen-signaling and gonadotropin pathways are associated with treatment outcomes, safety profiles and hormonal responses.
If approved, the trial would combine clinical outcomes, pharmacokinetic and pharmacodynamic measurements, hormonal biomarkers and genomic data in a single dataset, an approach that reflects broader efforts across the pharmaceutical industry to identify patient populations most likely to benefit from specific therapies.
Medicus Executive Chairman and Chief Executive Officer Dr. Raza Bokhari characterized the study as an effort to apply precision medicine principles to a disease that has traditionally been treated with broader hormonal approaches.
“To our knowledge, this is among the first prospective studies evaluating a long-acting GnRH antagonist in endometriosis through a precision medicine framework,” Bokhari said.
Investigators will evaluate whether Teverelix can achieve estradiol suppression within the therapeutic range commonly associated with symptom control while limiting side effects linked to estrogen depletion, including vasomotor symptoms and bone loss.
In addition to symptom and quality-of-life assessments, researchers plan to monitor bone-turnover markers, hormonal responses, immunogenicity and drug-exposure data.
Endometriosis affects an estimated one in 10 women of reproductive age worldwide and is associated with chronic pelvic pain, infertility and reduced quality of life. Despite the availability of multiple treatments, many patients experience recurring symptoms, adverse effects or limited long-term benefit.
Medicus believes data from the study could support future mid-stage clinical development of Teverelix in endometriosis and potentially inform research in other estrogen-driven conditions, including uterine fibroids.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.